Brief: Medicenna Presents Promising Clinical Data From Phase 2B Recurrent Glioblastoma Trial Of Mdna55

Medicenna Therapeutics

07/02/2019 12:36

Feb 7 (Reuters) - Medicenna Therapeutics Corp  MDNA.TO :
    * MEDICENNA PRESENTS PROMISING CLINICAL DATA FROM PHASE 2B
RECURRENT GLIOBLASTOMA TRIAL OF MDNA55
    * MEDICENNA THERAPEUTICS CORP - STRONG INTERIM SURVIVAL
TREND
(15.2 VERSUS 8.5 MONTHS) EMERGING IN IL4R POSITIVE PATIENTS
    * MEDICENNA - ENROLMENT IN SECOND HALF OF STUDY
INCORPORATING
HIGHER DOSE OF MDNA55 EXPECTED TO BE COMPLETED IN NEXT COUPLE OF
MONTHS

Source text for Eikon:  ID:nPn6ZDrkda 
Further company coverage:  MDNA.TO 

 ((Reuters Messaging: Reuters.Briefs@thomsonreuters.com))